Research Paper Volume 13, Issue 2 pp 2851—2863

A novel methylation signature predicts inferior outcome of patients with PDAC

Minqi Gu1, *, , Jing Sun1, *, , Shunhao Zhang1, *, , Jing Chen1, , Guihua Wang1,2, , Shaoqing Ju1,2, , Xudong Wang1,2, ,

  • 1 Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
  • 2 School of Public Health, Nantong University, Nantong, Jiangsu, China
* Equal contribution

Received: May 26, 2020       Accepted: November 10, 2020       Published: January 10, 2021
How to Cite

Copyright: © 2021 Gu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Pancreatic ductal adenocarcinoma (PDAC) will become the second most common cause of death in North America and Europe over the next 10 years owing to the lack of early diagnosis, poor treatment, and poor prognosis. This study evaluated the methylation array data of 184 patients with PDAC in The Cancer Genome Atlas database to explore methylation biomarkers related to patient outcome. Using Univariable Cox regression analysis and Lasso regression analysis method in the training dataset, it was found that the four DNA methylation markers (CCNT1, ITGB3, SDS, and HMOX2) were significantly correlated with the overall survival of patients with PDAC. Kaplan–Meier analysis showed that these four DNA methylation markers could significantly distinguish high-risk and low-risk patients. Receiver operating characteristic analysis further confirmed that the four DNA methylation markers had high sensitivity and specificity, which could predict the prognosis of patients. Moreover, there was a difference in the genetic mutations between high-risk and low-risk patients distinguished by the four-DNA methylation model, which can provide information for clinical treatment. Finally, compared with known biomarkers, the model was more accurate in predicting the prognosis of PDAC. This four-DNA methylation model has potential as a new independent prognostic indicator, and could be used for the diagnosis, monitoring, and precision medicine of pancreatic cancer.


AUC: Area under the ROC curve; OS: Overall survival; ROC: Receiver operating characteristic; TCGA: The Cancer Genome Atlas; PDAC: Pancreatic ductal adenocarcinoma.